Frazier Life Sciences Management as of March 31, 2024
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 50 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 12.2 | $289M | 12M | 23.65 | |
| Krystal Biotech (KRYS) | 7.4 | $176M | 989k | 177.93 | |
| Mirum Pharmaceuticals (MIRM) | 6.9 | $163M | 6.5M | 25.12 | |
| Hillevax (HLVX) | 6.9 | $163M | 9.8M | 16.63 | |
| Alpine Immune Sciences | 5.2 | $124M | 3.1M | 39.64 | |
| Phathom Pharmaceuticals (PHAT) | 4.5 | $107M | 10M | 10.62 | |
| Bridgebio Pharma (BBIO) | 4.5 | $106M | 3.4M | 30.92 | |
| Rhythm Pharmaceuticals (RYTM) | 4.0 | $95M | 2.2M | 43.33 | |
| Arcutis Biotherapeutics (ARQT) | 3.7 | $87M | 8.8M | 9.91 | |
| Vaxcyte (PCVX) | 3.3 | $78M | 1.1M | 68.31 | |
| Tarsus Pharmaceuticals (TARS) | 2.7 | $65M | 1.8M | 36.35 | |
| Edgewise Therapeutics (EWTX) | 2.5 | $60M | 3.3M | 18.24 | |
| Oric Pharmaceuticals (ORIC) | 2.4 | $57M | 4.1M | 13.75 | |
| Apellis Pharmaceuticals (APLS) | 2.2 | $52M | 885k | 58.78 | |
| Disc Medicine (IRON) | 2.1 | $49M | 785k | 62.26 | |
| Verona Pharma Sponsored Ads (VRNA) | 2.0 | $49M | 3.0M | 16.09 | |
| Kalvista Pharmaceuticals (KALV) | 1.8 | $44M | 3.7M | 11.86 | |
| Rocket Pharmaceuticals (RCKT) | 1.8 | $42M | 1.6M | 26.94 | |
| Soleno Therapeutics (SLNO) | 1.6 | $38M | 876k | 42.80 | |
| Macrogenics (MGNX) | 1.5 | $36M | 2.5M | 14.72 | |
| Aerovate Therapeutics (AVTE) | 1.5 | $36M | 1.2M | 29.57 | |
| Cg Oncology (CGON) | 1.4 | $34M | 770k | 43.90 | |
| Merus N V (MRUS) | 1.4 | $34M | 747k | 45.03 | |
| Revolution Medicines (RVMD) | 1.4 | $32M | 998k | 32.23 | |
| Autolus Therapeutics Spon Ads (AUTL) | 1.2 | $30M | 4.6M | 6.38 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 1.1 | $27M | 629k | 42.86 | |
| Trevi Therapeutics (TRVI) | 1.1 | $26M | 7.4M | 3.45 | |
| Silence Therapeutics Ads (SLN) | 1.0 | $25M | 1.1M | 21.60 | |
| Deciphera Pharmaceuticals | 1.0 | $23M | 1.5M | 15.73 | |
| Pepgen (PEPG) | 0.9 | $22M | 1.5M | 14.70 | |
| Anaptysbio Inc Common (ANAB) | 0.9 | $20M | 900k | 22.52 | |
| Savara (SVRA) | 0.8 | $20M | 4.0M | 4.98 | |
| Cerevel Therapeutics Hldng I (CERE) | 0.7 | $17M | 393k | 42.27 | |
| Agios Pharmaceuticals (AGIO) | 0.6 | $15M | 523k | 29.24 | |
| Adverum Biotechnologies | 0.6 | $15M | 1.1M | 14.14 | |
| Puma Biotechnology (PBYI) | 0.6 | $15M | 2.8M | 5.30 | |
| Tyra Biosciences (TYRA) | 0.6 | $14M | 832k | 16.40 | |
| Applied Therapeutics (APLT) | 0.6 | $13M | 2.0M | 6.80 | |
| Allogene Therapeutics (ALLO) | 0.5 | $13M | 2.9M | 4.47 | |
| Arvinas Ord (ARVN) | 0.5 | $12M | 285k | 41.28 | |
| 89bio (ETNB) | 0.5 | $12M | 1.0M | 11.64 | |
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $8.7M | 470k | 18.49 | |
| Cogent Biosciences (COGT) | 0.3 | $6.3M | 937k | 6.72 | |
| Intellia Therapeutics (NTLA) | 0.2 | $5.6M | 204k | 27.51 | |
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.2 | $5.5M | 500k | 11.04 | |
| An2 Therapeutics (ANTX) | 0.2 | $4.5M | 1.4M | 3.25 | |
| Metagenomi (MGX) | 0.1 | $2.9M | 279k | 10.55 | |
| Gritstone Oncology Ord (GRTSQ) | 0.1 | $2.6M | 1.0M | 2.57 | |
| Bluebird Bio (BLUE) | 0.1 | $2.2M | 1.7M | 1.28 | |
| Aclaris Therapeutics (ACRS) | 0.0 | $328k | 264k | 1.24 |
